Grant of share options

RNS Number : 1956O

Shield Therapeutics PLC

15 May 2018

 

Shield Therapeutics plc

(the "Company")

Grant of share options

London, UK, 15 May 2018. Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company, with an initial focus on addressing iron deficiency, announces that on 14^th May 2018 it granted share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under the Company's Retention and Performance Share Plan, Bonus Share Plan and Company Share Option Plan.  The plans are designed to provide staff with rewards alongside increases in shareholder value, as well as provide the Company with a meaningful retention tool.

If specific performance targets are achieved the Retention and Performance Share Plan awards, exercisable at a price of 1.5p, vest on 31 December 2018 and 31 December 2020.  The Bonus Share Plan awards, which have been issued in lieu of the normal cash bonus payments for achievements during 2017 and are also exercisable at 1.5p, will vest on 31 May 2019. The Company Share Option Plan has an exercise price of 25.5p per Ordinary Share and vests on 14 May 2021.

The Company has the capacity to issue up to 10% of its issued share capital in the form of Options.  Following these grants the total number of Ordinary Shares outstanding under all existing share incentive scheme arrangements is now 6,476,459, representing 5.6% of the Company's issued share capital. 

In accordance with the requirements of the EU Market Abuse Regulations the following options have been granted to PDMRs:

Name	Option	Number of Ordinary Shares under Option	Vesting Date
Mark Sampson PDMR	Retention and Performance Share Plan	135,000	31 December 2018
Carl Sterritt         CEO	Bonus Share Plan	317,184	31 May 2019
Mark Sampson PDMR	Bonus Share Plan	162,000	31 May 2019
Carl Sterritt         CEO	Retention and Performance Share Plan	970,867	31 December 2020
Mark Sampson PDMR	Retention and Performance Share Plan	364,500	31 December 2020

Notification and public disclosure of transactions by PDMRs and persons closely associated with them

Retention and Performance Share Plan

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Carl Sterritt - Founder, Director and PDMR Mark Sampson - PDMR
2.	Reason for the notification
a)	Position / status	PDMRs
b)	Initial notification / amendment	Initial notification
3.	Details of the issuer
a)	Name	Shield Therapeutics plc
b)	LEI	213800G74QWY15FC3W71
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 1.5p each.
b)	Identification code	GB00BYV81293
c)	Nature of the transaction	Grant of options over ordinary shares under the Shield Therapeutics Retention Share Plan.
d)	Price(s) and volume(s)	Exercise price: 1.5p Volumes: Carl Sterritt 970,867 Mark Sampson 499,500
e)	Aggregated information -     Volume -     Price	1,470,367 Exercise price: 1.5p
f)	Date of the transaction	14th May 2018
g)	Place of the transaction	Outside a trading venue

Bonus Share Plan

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Carl Sterritt - Director/PDMR Mark Sampson - PDMR
2.	Reason for the notification
a)	Position / status	PDMRs
b)	Initial notification / amendment	Initial notification
3.	Details of the issuer
a)	Name	Shield Therapeutics plc
b)	LEI	213800G74QWY15FC3W71
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 1.5p each.
b)	Identification code	GB00BYV81293
c)	Nature of the transaction	Grant of options over ordinary shares under the Shield Therapeutics Bonus Share Plan.
d)	Price(s) and volume(s)	Exercise price: 1.5p Volumes: Carl Sterritt 317,184 Mark Sampson 162,000
e)	Aggregated information -     Volume -     Price	479,184 Exercise price: 1.5p
f)	Date of the transaction	14th May 2018
g)	Place of the transaction	Outside a trading venue

-Ends-

For further information please contact:

Shield Therapeutics plc                                                                                                       [phone]

Carl Sterritt, Chief Executive Officer

Karl Keegan, Interim Chief Financial Officer

Nominated Advisor and Joint Broker                                                                              [phone]

Liberum Capital Limited

Christopher Britton/Steve Pearce

Joint Broker                                                                                                                          [phone]

Peel Hunt LLP

James Steel/Christopher Golden

Financial PR Advisor                                                                                                            [phone]

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

About Shield Therapeutics plc

Shield Therapeutics is a commercial stage pharmaceutical company, delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of all adults with iron deficiency with or without anaemia which has exclusive IP rights until the mid-2030's.  For more information please visit www.shieldtherapeutics.com.

 

END

 

 

DSHUVUBRWRAVAAR